Breast Cancer

Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for patients with endocrine-resistant, hormone receptor–positive, metastatic breast cancer, says Aditya Bardia, MD, MPH.

Trastuzumab deruxtecan produces the longest time to next treatment in patients with HER2-positive or stable HER2-low advanced breast cancer in the RELIEVE study.

The DEBBRAH trial met its primary endpoint of overall survival in a cohort of patients with HER2-positive or HER2-low advanced breast cancer and leptomeningeal carcinomatosis with positive cerebrospinal fluid cytology.

Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.

Data highlight the importance of genomic testing to help optimize treatment and reduce disparities for Black patients with hormone receptor–positive HER2-negative breast cancer, according to Sonya Reid, MD, MPH.

Trastuzumab emtansine plus tucatinib has promising clinical activity and a manageable safety profile in HER2-positive metastatic breast cancer, says Sara A. Hurvitz, MD.

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.

The pembrolizumab-based regimen in the phase 3 KEYNOTE-756 trial produces a larger pathologic complete response benefit in patients with node-positive disease and higher PD-L1 expression, according to Joyce O’Shaughnessy, MD.

Preclinical research supports the rationale of combining a BDC-1001 surrogate with pertuzumab to target HER2-expressing tumors.

A future planned analysis of the monarchE trial may further define how circulating tumor DNA dynamics can help identify patients with hormone receptor–positive HER2-negative breast cancer who are at high risk of recurrence.

Combining capivasertib with fulvestrant improves time to deterioration compared with placebo plus fulvestrant among patients with hormone receptor–positive, HER2-negative breast cancer in the CAPItello-291 trial.

Partial breast irradiation is associated with lower financial toxicities and fewer AEs in patients with early-stage breast cancer compared with whole breast irradiation.

Future-looking models see a large decrease in the cost of running sentinel lymph node assessments when artificial intelligence is used.

Combining ribociclib with endocrine therapy appears to be effective and tolerable for those with hormone receptor–positive HER2-negative advanced breast cancer, including elderly patients.

The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.

Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.

Companion diagnostic designation for FoundationOne CDx may improve access to treatment with capivasertib plus fulvestrant among patients with hormone receptor–positive, HER2-negative breast cancer harboring select alterations.

Additional research is needed to confirm whether capivasertib/fulvestrant offers increased benefit in patients with locally advanced or metastatic breast cancer not harboring AKT pathway alterations.

Paolo Tarantino, MD, gives an overview on how the recently approved combination of capivasertib plus fulvestrant can help improve treatment strategies for patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer

Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.

Sara M. Tolaney, MD, MPH, gives an extensive overview on the current breast cancer landscape and available treatment options.

Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.

The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.

Investigators are assessing rhenium obisbemeda as a treatment for breast cancer harboring leptomeningeal metastases as part of the phase 1/2a ReSPECT-LM trial.

Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.

Patients with breast cancer harboring BRCA1/2 mutations appear to be more likely to undergo mastectomies than those without, according to Zachary Kiss, DO.

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Paige Lymph Node is the first artificial intelligence application of its kind to receive breakthrough device designation from the FDA for detecting breast cancer metastases.

Sara M. Tolaney, MD, MPH, concludes the program with advice for community oncologists who are treating patients with breast cancer.